Phathom Pharmaceuticals, Inc.
PHATNasdaqCIK 1783183HealthcareFiscal year ends Dec 31
Reports and events: 156 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2024-05-0908:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-134793 |
| 2024-04-1216:03 ET | DEF 14A | Proxy statementPeriod 2024-05-23 | 0000950170-24-044015 |
| 2024-03-0716:01 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-027910 |
| 2024-03-0708:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-061512 |
| 2024-02-1308:05 ET | 8-K | 8.01 Other events | 0001193125-24-032946 |
| 2023-12-1516:05 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-23-296630 |
| 2023-12-1408:05 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001193125-23-294942 |
| 2023-12-0608:05 ET | 8-K | 8.01 Other events | 0001193125-23-289582 |
| 2023-11-2808:06 ET | 8-K | 8.01 Other events | 0001193125-23-283719 |
| 2023-11-0908:05 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-061554 |
| 2023-11-0908:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-274082 |
| 2023-11-0117:06 ET | 8-K | 8.01 Other events | 0001193125-23-268319 |
| 2023-10-3008:05 ET | 8-K | 8.01 Other events | 0001193125-23-265692 |
| 2023-09-2608:05 ET | 8-K | 8.01 Other events | 0001193125-23-241941 |
| 2023-08-2108:07 ET | 8-K | 8.01 Other events | 0001193125-23-216611 |
| 2023-08-1016:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-209005 |
| 2023-08-1008:06 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-040977 |
| 2023-07-1716:04 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-23-188097 |
| 2023-06-1509:05 ET | 8-K | 8.01 Other events | 0001193125-23-167476 |
| 2023-06-1208:05 ET | 8-K | 8.01 Other events | 0001193125-23-164930 |
| 2023-05-3017:16 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-156713 |
| 2023-05-2617:29 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-23-155579 |
| 2023-05-2416:14 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-152946 |
| 2023-05-2316:03 ET | 8-K | 8.01 Other events | 0001193125-23-151785 |
| 2023-05-1008:19 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-020109 |
| 2023-05-1008:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-140078 |
| 2023-05-0516:13 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-23-137114 |
| 2023-04-1316:03 ET | DEF 14A | Proxy statementPeriod 2023-05-25 | 0000950170-23-012704 |
| 2023-04-0408:06 ET | 8-K | 8.01 Other events | 0001193125-23-090354 |
| 2023-02-2808:06 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-004875 |
| 2023-02-2808:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-052344 |
| 2023-02-0916:06 ET | 8-K | 8.01 Other events | 0001193125-23-030011 |
| 2023-01-0906:07 ET | 8-K | 8.01 Other events | 0001193125-23-004049 |
| 2023-01-0316:09 ET | 8-K | 8.01 Other events | 0001193125-23-000749 |
| 2022-11-0908:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-22-280741 |
| 2022-11-0917:56 ET | 10-Q/A | Quarterly report, amendedPeriod 2022-09-30 | 0000950170-22-023372 |
| 2022-11-0815:31 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-023160 |
| 2022-11-0108:05 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-22-274514 |
| 2022-10-2408:05 ET | 8-K | 8.01 Other events | 0001193125-22-267152 |
| 2022-09-2908:01 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-22-253755 |
| 2022-09-2616:00 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-22-251241 |
| 2022-09-2608:06 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-22-250665 |
| 2022-08-1115:55 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-22-218481 |
| 2022-08-0416:06 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-22-212499 |
| 2022-08-0208:25 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-22-209506 |
| 2022-08-0208:16 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000950170-22-013743 |
| 2022-05-2716:06 ET | 8-K | 5.07 Shareholder vote results; 8.01 Other events | 0001193125-22-162331 |
| 2022-05-2508:05 ET | 8-K | 8.01 Other events | 0001193125-22-159128 |
| 2022-05-1008:16 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0000950170-22-008741 |
| 2022-05-1008:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-22-145742 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 11, 2026, 03:04 ET. Listed shows no prices and gives no investment advice.